Dow Jones
34.053,94 -39,02 (-0,11%) Nasdaq
12.200,82 +384,50 (+3,25%) Nikkei 225
27.509,46 +107,41 (+0,39%) EUR/USD
1,0905 -0,0006 (-0,05%) BTC-EUR
21.584,93 -416,03 (-1,89%) CMC Crypto 200
536,94 -8,37 (-1,54%)
Incyte Corporation (0J9P.L)
- GlobeNewswire
Knight Therapeutics Announces Regulatory Submission for Tafasitamab in Brazil
MONTREAL, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Brazilian affiliate, United Medical Ltd., has submitted a marketing authorization application for tafasitamab in combination with lenalidomide to ANVISA, the Brazilian health regulatory agency, for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not eligible for auto
- GlobeNewswire
Actuate Therapeutics Announces First Patient Enrolled in Phase 2 Clinical Trial of Elraglusib Plus Retifanlimab as Investigational First Line Therapy for Patients With Advanced Pancreatic Cancer
Elraglusib combination Phase 2 trial with retifanlimab based on observed synergy with immune checkpoint inhibitors, and preclinical and early clinical data supporting immunomodulatory activity of GSK-3β inhibitorsCHICAGO and FORT WORTH, Texas, March 01, 2022 (GLOBE NEWSWIRE) -- Actuate Therapeutics and The University of Kansas Cancer Center today announced the enrollment of the first patient on a Phase 2 study of elraglusib (9-ING-41) plus retifanlimab combined with gemcitabine/nab-paclitaxel fo
